Xinyu Gui, Yuhong Liu, Ying Yan, Lijun Di, Guohong Song
{"title":"依维莫司治疗激素受体阳性乳腺癌患者的临床结果：一项现实世界分析。","authors":"Xinyu Gui, Yuhong Liu, Ying Yan, Lijun Di, Guohong Song","doi":"10.1080/14796694.2025.2567485","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The study aimed to evaluate the effectiveness and safety of everolimus combined with endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.</p><p><strong>Methods: </strong>Data from adult patients with HR+/HER2- advanced breast cancer at Beijing Cancer Hospital between January 2012 and February 2025 were analyzed retrospectively.</p><p><strong>Results: </strong>A total of 137 patients were included and the median progression-free survival (PFS) was 4.13 months (95% confidence interval [CI]: 2.86-5.40). The objective response rate and disease control rate (DCR) were 10.9% and 51.1%, respectively. No significant difference was found in PFS between different lines of therapy (p = 0.433) or different combination drugs with everolimus (p = 0.528). The median PFS in patients without prior use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors was 4.20 months, compared to 3.07 months in patients previously treated with CDK4/6 inhibitors (p = 0.466). The patients with prior CDK4/6 inhibitors for more than six months exhibited an extended PFS when subsequently treated with everolimus plus endocrine therapy (7.63 vs. 2.03 months, p<0.001). Meanwhile, everolimus-based treatment was generally well-tolerated.</p><p><strong>Conclusion: </strong>For patients with HR+/HER2- advanced breast cancer, everolimus combined with endocrine therapy may serve as an alternative option after disease progression on CDK4/6 inhibitors.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-9"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical outcomes of everolimus in patients with hormone receptor positive breast cancer: a real-world analysis.\",\"authors\":\"Xinyu Gui, Yuhong Liu, Ying Yan, Lijun Di, Guohong Song\",\"doi\":\"10.1080/14796694.2025.2567485\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>The study aimed to evaluate the effectiveness and safety of everolimus combined with endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.</p><p><strong>Methods: </strong>Data from adult patients with HR+/HER2- advanced breast cancer at Beijing Cancer Hospital between January 2012 and February 2025 were analyzed retrospectively.</p><p><strong>Results: </strong>A total of 137 patients were included and the median progression-free survival (PFS) was 4.13 months (95% confidence interval [CI]: 2.86-5.40). The objective response rate and disease control rate (DCR) were 10.9% and 51.1%, respectively. No significant difference was found in PFS between different lines of therapy (p = 0.433) or different combination drugs with everolimus (p = 0.528). The median PFS in patients without prior use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors was 4.20 months, compared to 3.07 months in patients previously treated with CDK4/6 inhibitors (p = 0.466). The patients with prior CDK4/6 inhibitors for more than six months exhibited an extended PFS when subsequently treated with everolimus plus endocrine therapy (7.63 vs. 2.03 months, p<0.001). Meanwhile, everolimus-based treatment was generally well-tolerated.</p><p><strong>Conclusion: </strong>For patients with HR+/HER2- advanced breast cancer, everolimus combined with endocrine therapy may serve as an alternative option after disease progression on CDK4/6 inhibitors.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2567485\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2567485","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Clinical outcomes of everolimus in patients with hormone receptor positive breast cancer: a real-world analysis.
Aims: The study aimed to evaluate the effectiveness and safety of everolimus combined with endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.
Methods: Data from adult patients with HR+/HER2- advanced breast cancer at Beijing Cancer Hospital between January 2012 and February 2025 were analyzed retrospectively.
Results: A total of 137 patients were included and the median progression-free survival (PFS) was 4.13 months (95% confidence interval [CI]: 2.86-5.40). The objective response rate and disease control rate (DCR) were 10.9% and 51.1%, respectively. No significant difference was found in PFS between different lines of therapy (p = 0.433) or different combination drugs with everolimus (p = 0.528). The median PFS in patients without prior use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors was 4.20 months, compared to 3.07 months in patients previously treated with CDK4/6 inhibitors (p = 0.466). The patients with prior CDK4/6 inhibitors for more than six months exhibited an extended PFS when subsequently treated with everolimus plus endocrine therapy (7.63 vs. 2.03 months, p<0.001). Meanwhile, everolimus-based treatment was generally well-tolerated.
Conclusion: For patients with HR+/HER2- advanced breast cancer, everolimus combined with endocrine therapy may serve as an alternative option after disease progression on CDK4/6 inhibitors.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
